435 related articles for article (PubMed ID: 17660383)
1. A novel oral indoline-sulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinamide (J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule.
Liou JP; Hsu KS; Kuo CC; Chang CY; Chang JY
J Pharmacol Exp Ther; 2007 Oct; 323(1):398-405. PubMed ID: 17660383
[TBL] [Abstract][Full Text] [Related]
2. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo.
Kuo CC; Hsieh HP; Pan WY; Chen CP; Liou JP; Lee SJ; Chang YL; Chen LT; Chen CT; Chang JY
Cancer Res; 2004 Jul; 64(13):4621-8. PubMed ID: 15231674
[TBL] [Abstract][Full Text] [Related]
3. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo.
Wong VK; Chiu P; Chung SS; Chow LM; Zhao YZ; Yang BB; Ko BC
Clin Cancer Res; 2005 Aug; 11(16):6002-11. PubMed ID: 16115945
[TBL] [Abstract][Full Text] [Related]
4. XN05, a novel synthesized microtubule inhibitor, exhibits potent activity against human carcinoma cells in vitro.
Wu R; Ding W; Liu T; Zhu H; Hu Y; Yang B; He Q
Cancer Lett; 2009 Nov; 285(1):13-22. PubMed ID: 19647933
[TBL] [Abstract][Full Text] [Related]
5. N-(2,6-dimethoxypyridine-3-yl)-9-methylcarbazole-3-sulfonamide as a novel tubulin ligand against human cancer.
Wang YM; Hu LX; Liu ZM; You XF; Zhang SH; Qu JR; Li ZR; Li Y; Kong WJ; He HW; Shao RG; Zhang LR; Peng ZG; Boykin DW; Jiang JD
Clin Cancer Res; 2008 Oct; 14(19):6218-27. PubMed ID: 18829501
[TBL] [Abstract][Full Text] [Related]
6. Salvinal, a novel microtubule inhibitor isolated from Salvia miltiorrhizae Bunge (Danshen), with antimitotic activity in multidrug-sensitive and -resistant human tumor cells.
Chang JY; Chang CY; Kuo CC; Chen LT; Wein YS; Kuo YH
Mol Pharmacol; 2004 Jan; 65(1):77-84. PubMed ID: 14722239
[TBL] [Abstract][Full Text] [Related]
7. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
8. Quinolone analogue inhibits tubulin polymerization and induces apoptosis via Cdk1-involved signaling pathways.
Chen YC; Lu PH; Pan SL; Teng CM; Kuo SC; Lin TP; Ho YF; Huang YC; Guh JH
Biochem Pharmacol; 2007 Jun; 74(1):10-9. PubMed ID: 17475221
[TBL] [Abstract][Full Text] [Related]
9. MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps.
Kasibhatla S; Baichwal V; Cai SX; Roth B; Skvortsova I; Skvortsov S; Lukas P; English NM; Sirisoma N; Drewe J; Pervin A; Tseng B; Carlson RO; Pleiman CM
Cancer Res; 2007 Jun; 67(12):5865-71. PubMed ID: 17575155
[TBL] [Abstract][Full Text] [Related]
10. A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors.
Tahir SK; Han EK; Credo B; Jae HS; Pietenpol JA; Scatena CD; Wu-Wong JR; Frost D; Sham H; Rosenberg SH; Ng SC
Cancer Res; 2001 Jul; 61(14):5480-5. PubMed ID: 11454695
[TBL] [Abstract][Full Text] [Related]
11. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.
Loganzo F; Discafani CM; Annable T; Beyer C; Musto S; Hari M; Tan X; Hardy C; Hernandez R; Baxter M; Singanallore T; Khafizova G; Poruchynsky MS; Fojo T; Nieman JA; Ayral-Kaloustian S; Zask A; Andersen RJ; Greenberger LM
Cancer Res; 2003 Apr; 63(8):1838-45. PubMed ID: 12702571
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo studies of a novel potential anticancer agent of isochaihulactone on human lung cancer A549 cells.
Chen YL; Lin SZ; Chang JY; Cheng YL; Tsai NM; Chen SP; Chang WL; Harn HJ
Biochem Pharmacol; 2006 Jul; 72(3):308-19. PubMed ID: 16782069
[TBL] [Abstract][Full Text] [Related]
13. Orally active microtubule-targeting agent, MPT0B271, for the treatment of human non-small cell lung cancer, alone and in combination with erlotinib.
Tsai AC; Wang CY; Liou JP; Pai HC; Hsiao CJ; Chang JY; Wang JC; Teng CM; Pan SL
Cell Death Dis; 2014 Apr; 5(4):e1162. PubMed ID: 24722287
[TBL] [Abstract][Full Text] [Related]
14. Double blockade of cell cycle at g(1)-s transition and m phase by 3-iodoacetamido benzoyl ethyl ester, a new type of tubulin ligand.
Jiang JD; Denner L; Ling YH; Li JN; Davis A; Wang Y; Li Y; Roboz J; Wang LG; Perez-Soler R; Marcelli M; Bekesi G; Holland JF
Cancer Res; 2002 Nov; 62(21):6080-8. PubMed ID: 12414632
[TBL] [Abstract][Full Text] [Related]
15. Huang-lian-jie-du-tang, a traditional Chinese medicine prescription, induces cell-cycle arrest and apoptosis in human liver cancer cells in vitro and in vivo.
Hsu YL; Kuo PL; Tzeng TF; Sung SC; Yen MH; Lin LT; Lin CC
J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 2):e290-9. PubMed ID: 18522681
[TBL] [Abstract][Full Text] [Related]
16. DAT-230, a novel microtubule inhibitor, exhibits potent anti-tumor activity by inducing G2/M phase arrest, apoptosis in vitro and perfusion decrease in vivo to HT-1080.
Qiao F; Zuo D; Shen X; Qi H; Wang H; Zhang W; Wu Y
Cancer Chemother Pharmacol; 2012 Aug; 70(2):259-70. PubMed ID: 22752214
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin.
Yoshimatsu K; Yamaguchi A; Yoshino H; Koyanagi N; Kitoh K
Cancer Res; 1997 Aug; 57(15):3208-13. PubMed ID: 9242451
[TBL] [Abstract][Full Text] [Related]
18. The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-alpha production with antitumor activity.
Zhang LH; Wu L; Raymon HK; Chen RS; Corral L; Shirley MA; Narla RK; Gamez J; Muller GW; Stirling DI; Bartlett JB; Schafer PH; Payvandi F
Cancer Res; 2006 Jan; 66(2):951-9. PubMed ID: 16424030
[TBL] [Abstract][Full Text] [Related]
19. Identification of tubulin as the molecular target of proapoptotic pyrrolo-1,5-benzoxazepines.
Mulligan JM; Greene LM; Cloonan S; Mc Gee MM; Onnis V; Campiani G; Fattorusso C; Lawler M; Williams DC; Zisterer DM
Mol Pharmacol; 2006 Jul; 70(1):60-70. PubMed ID: 16571652
[TBL] [Abstract][Full Text] [Related]
20. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.
Lee FY; Smykla R; Johnston K; Menard K; McGlinchey K; Peterson RW; Wiebesiek A; Vite G; Fairchild CR; Kramer R
Cancer Chemother Pharmacol; 2009 Jan; 63(2):201-12. PubMed ID: 18350296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
